Aquestive (AQST) Q2 FY26 earnings call

Aquestive Therapeutics is on track to resubmit its Anaphylm NDA in Q3 2026, bolstered by positive human factors and PK study data addressing prior FDA concerns. The company is preparing for a potential launch with a focused allergist strategy and believes Anaphylm offers significant clinical differentiation in a growing epinephrine market. Strategic partnering for Libervant and ex-U.S. Anaphylm, alongside the advancement of AQST-108, aims to diversify future growth.